Healthcare Systems' Liquidity Challenge

Healthcare systems are facing rising operating pressure, thinner margins, and a harder question about how to manage liquidity across the balance sheet as capital needs become more uncertain. Liquidity is an issue, and an enterprise risk management approach that factors in organizational risks when setting investment strategy can help.

Seeking Alpha • 2 hours ago

ETF Showdown: XBI vs PBE, Which Biotech Fund Wins?

At first glance, SPDR S&P Biotech ETF (NYSEARCA:XBI) and Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) look like two flavors of the same bet on drug discovery.

24/7 Wall Street • Jul 24, 2026

Buying Biotech's Policy Discount With XBI And IBB: Most 'Feared' Nation Policy, Less-Than-Feared Damage

I initiate Buy ratings on SPDR S&P Biotech ETF and iShares Biotechnology ETF for 2026–2027, favoring XBI for higher upside. Biotech's rally reflects improving fundamentals: robust M&A, positive clinical data, improved financing, and more quantifiable policy risk, not indiscriminate multiple expansion. MFN drug-pricing risk is narrower than feared, with emerging policies fragmented by payer, product, geography, and voluntary manufacturer participation.

Seeking Alpha • Jul 21, 2026

Healthcare Rules State Street's Top 5 ETFs in Past Month

With well over 170 ETFs on the market covering diverse investment strategies, State Street offers a prime window into which funds — and market trends — are leading the pack in the near term. Key Takeaways: Across State Street's 170+ ETFs, the top five performers this past month are all tied to the healthcare industry.

ETF Trends • Jul 17, 2026

Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?

Invesco Pharmaceuticals ETF offers a higher dividend yield and lower five-year beta than State Street SPDR S&P Biotech ETF State Street SPDR S&P Biotech ETF holds 155 securities compared to 30 in Invesco Pharmaceuticals ETF Invesco Pharmaceuticals ETF has experienced a significantly smaller max drawdown of 17.5% over the last five years, compared to 54% for State Street SPDR S&P Biotech ETF

The Motley Fool • Jul 9, 2026

Stocks Look Shaky, But This Sector is Booming (Biotech)

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.

Zacks Investment Research • Jul 9, 2026

Biotech Euphoria Driven By Fundamentals

Current biotech euphoria is driven by fundamentals and M&A appetite, says Jonathan Faison, who runs ROTY Biotech Community. Focusing on high-conviction, late-stage and commercial biotech names with strong balance sheets, strategic value, and long-lived intellectual property.

Seeking Alpha • Jul 8, 2026

This ETF Is Up Nearly 17% in a Month and Doesn't Own a Single Share of Nvidia

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over the trailing month ending July 1, 2026, a run that would look right at home in the AI trade.

24/7 Wall Street • Jul 6, 2026

June's Top ETFs: Biotech & China Semiconductors Surge

June has been a month full of excitement in the ETF market. While commercial space and AI infrastructure attracted a significant amount of investor attention, biotechnology exposure comprises four out of the five top-performing equity ETFs as of June 29.

ETF Trends • Jul 1, 2026

Market rotation is the most prevalent factor for healthcare outperformance, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Power Lunch' to discuss the recent performance in the healthcare sector, why sentiment has turned and much more.

CNBC Television • Jun 30, 2026